Aclaris Therapeutics
Update in progressACRS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for immuno-inflammatory diseases in the United States. Its pipeline includes Bosakitug (ATI-045), a Phase 2 anti-TSLP antibody for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and COPD; ATI-2138, a Phase 2a ITK/JAK3 dual inhibitor; ATI-052, a Phase 1b bispecific anti-TSLP/IL-4R antibody; ATI-9494, an oral ITK/TXK dual inhibitor; and Lepzacitinib, a soft JAK1/3 inhibitor. Founded 2012, based in Wayne, PA.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Neal S. Walker D.O., M.D.
- Founded2012
- Employees69
- Websitewww.aclaristx.com
Identifiers
- ISINUS00461U1051
- FIGIBBG003LF0QR9
- LEI5493000B2LQ9QTW1DF52
- CUSIP00461U105
- CIK0001557746